Document 0344
 DOCN  M9440344
 TI    Continuous presence of CD4-PE40 is required for antiviral activity
       against single-passage HIV isolates and infected peripheral blood
       mononuclear cells.
 DT    9404
 AU    Winters MA; Merigan TC; Center for AIDS Research, Stanford University
       Medical Center,; California 94305.
 SO    AIDS Res Hum Retroviruses. 1993 Nov;9(11):1091-6. Unique Identifier :
       AIDSLINE MED/94145743
 AB    CD4-PE40, a recombinant protein consisting of a portion of human CD4
       linked to Pseudomonas aeruginosa exotoxin, was studied in vitro to
       assess its ability to inhibit the replication of primary isolates of
       HIV. CD4-PE40 was added to cultures of phytohemagglutin (PHA)-stimulated
       normal peripheral blood mononuclear cells (PBMCs) infected either with
       the laboratory strain HIVIIIb or single-passage virus stocks derived
       from patient PBMCs. Results showed that the replication of HIVIIIb was
       inhibited by a single pulse of CD4-PE40 and, more significantly, by
       continuous exposure to the drug. The replication of primary virus
       isolates, however, was inhibited only by continuous exposure to
       CD4-PE40. Cultures of freshly isolated PBMCs from HIV-seropositive
       individuals that were directly treated with CD4-PE40 before culture also
       required the continuous presence of drug to demonstrate inhibition of
       HIV replication. These results suggest that continuous administration of
       CD4-PE40 may be required to produce a significant anti-HIV effect in
       vivo.
 DE    Antiviral Agents/*PHARMACOLOGY  Exotoxins/*PHARMACOLOGY  Human  HIV Core
       Protein p24/BIOSYNTHESIS  HIV Envelope Protein gp120/METABOLISM  HIV
       Infections/DRUG THERAPY/MICROBIOLOGY  HIV-1/*DRUG EFFECTS/ISOLATION &
       PURIF/PHYSIOLOGY  Immunotoxins/*PHARMACOLOGY  In Vitro  Leukocytes,
       Mononuclear/DRUG EFFECTS/MICROBIOLOGY  Recombinant Proteins/PHARMACOLOGY
       Support, Non-U.S. Gov't  Virus Replication/DRUG EFFECTS  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).